



23 February 2021

Sydney, Australia

## Investor Presentation to Finance News Network CEO Showcase

**Sydney, 23 February 2021:** Nyrada Inc (ASX: NYR) is pleased to provide to shareholders and the market generally the corporate presentation that will be used by Nyrada CEO, James Bonnar at the Finance News Network CEO Showcase webinar to be held today, from 12.30pm (AEDT).

Mr Bonnar will provide an update on the progress of the Company's lead drug development programs.

The webinar is free to attend. To register for the event, please use the following link: <https://www.finnewsnetwork.com.au/page/investor-events>

A replay of the webinar will also be available to view after the event via the Company's website at: <https://www.nyrada.com/site/investors/presentations>

### About Nyrada Inc

Nyrada is a preclinical stage, drug discovery and development company, specialising in novel small molecule drugs to treat cardiovascular and neurological diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, USA, and the liability of its stockholders is limited.

[www.nyrada.com](http://www.nyrada.com)

*Authorised by John Moore, Non-Executive Chairman, on behalf of the Board.*

#### Investor & Corporate Enquiries:

Laura Vize  
Investor Relations Manager  
T: 0417 026 056  
E: [info@nyrada.com](mailto:info@nyrada.com)

#### Company Secretary:

David Franks  
T: 02 8072 1400  
E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)



**Media Enquiries:**

Catherine Strong

Citadel-MAGNUS

T: 02 8234 0111

E: [cstrong@citadelmagnus.com](mailto:cstrong@citadelmagnus.com)

**Forward-Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.



# INVESTOR PRESENTATION

Finance News Network CEO Showcase

James Bonnar  
Nyrada CEO

23 February 2021



# Important Notice & Disclaimer

This presentation has been prepared by Nyrada Inc (NYR or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NYR, or as an inducement to purchase any shares in NYR. No agreement to subscribe for securities in NYR will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licensed to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements do not guarantee of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.

Although the Company believes that the expectations reflected in the forward looking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making.

Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.

## Vision

**We can improve lives and offer hope through innovation**

-  Deliver a cost-competitive and convenient cholesterol-lowering treatment to help achieve target safe cholesterol level  
*Reduce risk of cardiovascular disease (heart attack and stroke)*
-  Deliver the first-ever treatment to prevent brain damage following stroke and head trauma (falls, motor vehicle accidents)  
*Improve survivability, reduce disability*

## Mission

**Advance our drug candidates towards value inflection and commercialise early**

# Business Strategy

Drug discovery  
and early-stage  
developer

## Cholesterol-Lowering drug

Oral *PCSK9 inhibitor* to be used alone as a monotherapy, or in combination with a statin  
- Out-license following Phase I study

## Brain Injury drug

*Intravenous* and *intranasal* drug to help people who sustain a traumatic brain injury (TBI) or suffer a stroke  
- Out-license following Phase II study

Innovative Treatments

Best-in-Class / First-Line

Clinical Need

Strong Patent Protection

Market Potential

Commercialise Early

# Problem – High LDL Cholesterol

**High LDL Cholesterol** leading cause of cardiovascular disease

**Cardiovascular disease** responsible for 1-in-4 deaths<sup>1</sup>

**62.6 million** US adults with elevated LDL-C<sup>2</sup>



1. Centers for Disease Control and Prevention, Heart Disease Facts: Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics—2020 update: a report from the American Heart Association.
2. Wong ND et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US. J Clin Lipidology. 2016


# Statin Drugs



Low cost



Suboptimal efficacy



**19.4 million**

Unable to achieve  
LDL-C target despite  
taking statin therapy

**27.4 million**

US adults with elevated  
LDL-C are taking a statin

# Current PCSK9 Inhibitors



Binds to PCSK9 protein

Blocks action of PCSK9  
on cholesterol receptor



Effective, combined with a statin



Expensive US\$5,800 per year  
Inconvenient (2-4 weekly injections)

**Statin + current PCSK9 inhibitor** = expensive and inconvenient

# What is Unique?


Oral PCSK9  
treatment

Convenient  
for patient


Cost-  
effective

Small molecule PCSK9 inhibitor  
overcomes longstanding challenge of  
**oral treatment**

Can be combined with statin  
to deliver a first ever  
**single pill PCSK9/statin treatment**



# Cholesterol Reduction with NYX-PCSK9i



% difference in plasma total cholesterol versus vehicle control (*p*-value)

| Time (days)          | 7                    | 14                        | 21                        | 28                        |
|----------------------|----------------------|---------------------------|---------------------------|---------------------------|
| 30 mg/kg NYX-PCSK9i  | -14% ( <b>0.05</b> ) | -23% ( <b>0.015</b> )     | -32% ( <b>0.002</b> )     | -36% ( <b>&lt;0.001</b> ) |
| 50 mg/kg NYX-PCSK9i  | -16% ( <b>0.05</b> ) | -40% ( <b>&lt;0.001</b> ) | -50% ( <b>&lt;0.001</b> ) | -57% ( <b>&lt;0.001</b> ) |
| Exploratory 10 mg/kg | 0% (0.95)            | -4% (0.505)               | -                         | -                         |
| Exploratory 75 mg/kg | -                    | -                         | -36% ( <b>&lt;0.001</b> ) | -48% ( <b>&lt;0.001</b> ) |

# Brain Injury Problem


## Each year in the US:

- 2.8 million people sustain a traumatic brain injury (TBI)
- 800,000 suffer a stroke

Neurology / physical rehabilitation are the only existing therapies


- One drug class for stroke (Suitable for less than 15% of patients)
- No treatment exists for TBI

- High mortality
- Severe life-long disability
- High ongoing healthcare cost




*Minutes*

**Initial injury size**



*Hours*




*Days*

**Final injury size**

# Nyrada Brain Injury Solution

- 📌 Treatment for secondary brain injury following Stroke or TBI
  - Prevent cell death
  - Attenuate damaged brain volume
  - Improve survivability, limit disability, improve quality of life



# Walter Reed & UNSW Collaboration

Nyrada  
inc

- Collaboration secured with the world-leading scientific teams at Walter Reed Army Institute of Research and UNSW Sydney
- Efficacy and mechanism of action studies to be conducted on Nyrada's preclinical neuroprotection compound
- Aligns with Walter Reed's mission to develop ground-breaking solutions to mitigate the impacts of traumatic brain injury which occurs in 1 in 25 military service members

**WRAIR**  
Walter Reed Army  
Institute of Research  
Soldier Health • World Health



***Signals industry interest in Nyrada's technology***

# Program Status & Recent Achievements

Proof-of-concept  
established



Lead optimisation well  
advanced



First-in-human studies  
(Phase I)

- Cholesterol-lowering Drug:  
**late-CY 2021**
- Brain Injury Drug:  
**mid-CY 2022**



-  Results from an *in vivo* cholesterol efficacy study showed a **57% reduction** in total cholesterol (announced on 21 December 2020)
-  Nyrada NYX-1010 showed excellent potency and blood-brain barrier penetration

# Board of Directors



**Mr John Moore**  
Non-Executive  
Chairman



**Dr Ian Dixon**  
Non-Executive  
Director



**Christopher Cox**  
Non-Executive  
Director



**Mr Peter Marks**  
Non-Executive  
Director



**Mr Marcus  
Frampton**  
Non-Executive  
Director



**Dr Rüdiger  
Weseloh**  
Non-Executive  
Director

-  **Nyrada operates under the direction of a board of international calibre**
-  **Track record in founding and realising the value of biotech companies**

# Key Metrics & News Flow

Market capitalisation  
(as at 22 February 2021) **\$39M**

Share price  
(as at 22 February 2021) **\$0.355**

CDIs free float **77,719,770**

CDIs 24 months escrow **33,105,853**

Cash at bank (31 Dec 2020) **A\$4.1m**

ASX listing **January 16, 2020**

| CY 2021 | CY 2022 |
|---------|---------|
|---------|---------|

Cholesterol-lowering program  
to enter clinic: ▲

Neuroprotection program  
to enter clinic: ▲



Further preclinical results: **ongoing**

Non-dilutive funding: **ongoing**

# Discover More & Follow Us

Nyrada  
inc



Neuroprotection Animation



Cholesterol-Lowering Animation

[info@nyrada.com](mailto:info@nyrada.com)  
[www.nyrada.com](http://www.nyrada.com)



[@nyrada\\_inc](https://twitter.com/nyrada_inc)



[@nyrada\\_inc](https://www.linkedin.com/company/nyrada_inc)



ASX: NYR